Trial · NCT06496581
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival (OS) | From randomization to death due to any cause, up to 8.5 years | Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. |
| Primary | Radiographic progression-free survival (rPFS) | From randomization to radiographic progression or death, up to 8.5 years | Radiographic progression-free survival (rPFS) is defined as the time from randomization to the date of radiographic progression according to PCWG3 criteria by investigator assessment, or death, whichever occurs first. |
| Secondary | Castration-Resistance Prostate Cancer-Free Survival (CRPC-FS) | From randomization to onset of castration-resistance or death, up to 8.5 years | Castration-Resistance Prostate Cancer-Free Survival (CRPC-FS) is defined as the time from randomization to the onset of castration-resistance or death from any cause, whichever occurs first. |
| Secondary | Prostate Cancer-Specific Survival (PCSS) | From the date of randomization to a PCSS event, up to 8.5 years | Prostate Cancer-Specific Survival (PCSS) is defined as the time from the date of randomization to the date of death due to prostate cancer. |
| Secondary | PSA response | From baseline over the treatment period, up to 8.5 years | PSA response will be assessed by the maximum change of PSA (rise or fall) from baseline over the treatment period. A complete PSA response is defined by an undetectable level of serum PSA. |
| Secondary | Skeletal-related event-free survival (SRE-FS) | From randomization to the onset of a SRE-FS event, up to 8.5 years | Skeletal-related event-free survival (SRE-FS) is defined as the time from the randomization date to the date of diagnosis of either a skeletal-related event (SRE) (fracture, or bone pain requiring radiation therapy, or spinal cord compression, or preventive surgery to the bones) or death, whichever occurs first. |
| Secondary | Time to severe urinary event (SUE) | From randomization to the onset of a SUE event, up to 8.5 years | Time to severe urinary event (SUE) is defined as the time from the randomization date to the date of diagnosis of either one of the following SUE, whichever occurs first: urinary retention with need for a urinary catheter, suprapubic catheter, double J stent, nephrostomy, treatment of the prostate by radiotherapy or trans-urethral resection of the prostate (TURP) or prostatectomy done to relieve patients with local symptoms. |
| Secondary | Time to initiation of first subsequent anti-cancer systemic therapy for CRPC (TTSST1) | From randomization to initiation of the first anti-cancer systemic therapy for CRPC, up to 10 years | TTSST1 is defined as the time from the randomization date to the date of initiation of the first anti-cancer systemic therapy for CRPC. |
| Secondary | Time to initiation of second subsequent anti-cancer systemic therapy for CRPC (TTSST2) | From randomization to initiation of the second anti-cancer systemic therapy for CRPC, up to 10 years | TTSST2 is defined as the time from the randomization date to the date of initiation of the second anti-cancer systemic therapy for CRPC. |
| Secondary | Efficacy of first subsequent anti-cancer systemic therapy for CRPC | From first anti-cancer systemic therapy for CRPC to disease progression or death, up to 10 years | Efficacy of subsequent anti-cancer systemic therapy for CRPC will be defined as the time from first anti-cancer systemic therapy for CRPC to disease progression or death from any cause, whichever comes first. |
| Secondary | Efficacy of second subsequent anti-cancer systemic therapy for CRPC | Fromsecond anti-cancer systemic therapy for CRPC to disease progression or death, up to 10 years | Efficacy of second subsequent anti-cancer systemic therapy for CRPC will be defined as the time from second anti-cancer systemic therapy for CRPC to disease progression or death from any cause, whichever comes first. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06496581/registered